Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846613 | 0.85 | CRHR1 (0.33) | CRHR1MAPK1 | |
| SCHEMBL5043549 | 0.81 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL5048460 | 0.80 | CRHR1 (0.39) | CRHR1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5046968 | 0.73 | CRHR1 (0.31) | CRHR1MAPTALDH1A1GAAHTT | |
| SCHEMBL6363497 | 0.70 | CRHR1 (0.32) | CRHR1 | |
| SCHEMBL5776900 | 0.70 | MEN1 (0.32) | CRHR1MEN1KMT2AALDH1A1 | |
| SCHEMBL5048818 | 0.67 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL5047415 | 0.67 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL5043421 | 0.66 | CRHR1 (0.31) | CRHR1GAA | |
| SCHEMBL5043842 | 0.65 | CRHR1 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1718299-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005077363-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | CRHR1 71/4885MAPK1 2868/4885MEN1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.